Ursodeoxycholic acid and its taurine- or glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice

Citation metadata

From: Applied and Environmental Microbiology(Vol. 83, Issue 7)
Publisher: American Society for Microbiology
Document Type: Report
Length: 76 words

Document controls

Main content

Abstract :

The impact of the secondary bile acid ursodeoxycholic acid (UDCA) and its taurine or glycine conjugates on the fecal microbial community structure during experimental colitis are examined. Illumina sequencing demonstrates that bile acid therapy during colitis did not restore fecal bacterial richness and diversity. It is concluded that UDCA, which is an FDA-approved drug for cholestatic liver disorders, could be an attractive treatment option to reduce dysbiosis and ameliorate inflammation in human inflammatory bowel diseases (IBD).

Source Citation

Source Citation   

Gale Document Number: GALE|A497137264